Conjugate Vaccine Market Forecast 2025-2034: Analysing Major Trends, Opportunities, and Growth Drivers

What industry-specific factors are fueling the growth of the conjugate vaccine market?
The rise in the application of conjugate vaccines among adults is predicted to fuel the expansion of the conjugate vaccine market. Conjugate vaccines are engineered to induce a potent immune response against bacterial capsular polysaccharides, thereby augmenting the body's protective response to bacterial infections. Utilizing conjugate vaccines in adults helps mitigate the risk of serious illness, complications, and spread of these bacterial diseases by provoking a sturdy immune response. For instance, in June 2024, reports from the UK Health Security Agency (UKHSA), a public health agency in the UK, indicated that the 12-month coverage for the '6-in-1' vaccine in the UK remained stable at 91.7%. The first dose of the pneumococcal conjugate vaccine (PCV) stood firm at 93.7%. The coverage for the Rotavirus saw a slight increase of 0.6%, achieving 89.3%, while the second dose of the meningitis B vaccine (MenB2) increased marginally by 0.1%, hitting 91.5%. Consequently, the rise in the application of conjugate vaccines for adults is bolstering the growth of the conjugate vaccine market.

Get Your Conjugate Vaccine Market Report Here:
https://www.thebusinessresearchcompany.com/report/conjugate-vaccine-global-market-report

What Is the projected market size and growth rate for the conjugate vaccine market?
In recent times, the market size of the conjugate vaccine has increased significantly. It is projected to rise from $18.9 billion in 2024 to approximately $21.46 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.5%. The expansion in the historic period is likely due to factors such as disease prevalence, government-led immunization initiatives, heightened awareness, a focus on pediatric vaccination, and trends in preventive healthcare.

In the coming years, the conjugate vaccine market size is predicted to experience a swift increase. It's expected to reach "$34.59 billion by 2029 with a compound annual growth rate (CAGR) of 12.7%. The anticipated expansion during the forecast period can be credited to a variety of factors including the broadening of immunization strategies, changing demographics of the aging population, introduction of new vaccine indications, concerns around global health security, international cooperation, and the impact of economic development. Leading trends for the future include cooperation and alliances for vaccine distribution, customized strategies for populations at high risk, utilization in developing infectious illnesses, progress in vaccine manufacturing technologies, and global health endeavors for vaccine fairness.

Get Your Free Sample Now - Explore Exclusive Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What new trends are reshaping the conjugate vaccine market and its opportunities?
The conjugate vaccine market is currently observing a rising trend in vaccine innovation. This is being driven by firms seeking to establish dominance in the market by creating novel conjugate vaccines. For instance, a prominent biotechnology and pharmaceutical entity from the US, Pfizer Inc., introduced in Canada, a pneumococcal 20-valent conjugate vaccine called Prevnar 20, in June 2022. This was targeted at preventing pneumonia and serious pneumococcal infections in individuals who are 18 years and above. Prevnar 20 is inclusive of conjugates for the 13 serotypes that were previously encompassed by PREVNAR 13, as well as conjugates for an additional seven serotypes. These serotypes are linked with severe pneumococcal disease, higher mortality rates, resistance to antibiotics, and meningitis.

What major market segments define the scope and growth of the conjugate vaccine market?
The conjugate vaccine market covered in this report is segmented -

1) By Product Type: Monovalent Conjugate Vaccines, Multivalent Conjugate Vaccine
2) By Pathogen: Bacterial, Viral
3) By Disease Indication: Pneumococcal, Influenza, Meningococcal, Typhoid
4) By Patient: Pediatric, Adults
5) By End-User: Hospitals, Clinics, Homecare Settings, Other End Users

Subsegments:
1) By Monovalent Conjugate Vaccines: Single Pathogen Conjugate Vaccines
2) By Multivalent Conjugate Vaccines: Multiple Pathogen Conjugate Vaccines, Combination Conjugate Vaccines

Unlock Exclusive Market Insights - Purchase Your Research Report Now!
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10850

Which region dominates the conjugate vaccine market?
North America was the largest region in the global conjugate vaccine market in 2024. The regions covered in the conjugate vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Which key market leaders are driving the conjugate vaccine industry growth?
Major companies operating in the conjugate vaccine market include Sanofi S.A., Pfizer Inc., Merck & Co. Inc., GlaxoSmithKline plc, Bharat Biotech International Limited, Serum Institute of India Private Limited, Biological E. Limited, Bavarian Nordic A/S, CSL Limited, Novartis AG, GreenSignal Bio Pharma Limited, Taj Pharmaceuticals Limited, Vaxcyte Inc., Neuron Biotech Co. Ltd., Bio-Med Pvt. Ltd., Sinovac Biotech Ltd., Takeda Pharmaceutical Company Limited, Valneva SE, Dynavax Technologies Corporation, Emergent BioSolutions Inc., Hualan Biological Engineering Inc., Panacea Biotec Ltd., Protein Sciences Corporation, Seqirus

Customize Your Report - Get Tailored Market Insights!
https://www.thebusinessresearchcompany.com/sample.aspx?id=10850&type=smp

What Is Covered In The Conjugate Vaccine Global Market Report?

• Market Size Forecast: Examine the conjugate vaccine market size across key regions, countries, product categories, and applications.
• Segmentation Insights: Identify and classify subsegments within the conjugate vaccine market for a structured understanding.
• Key Players Overview: Analyze major players in the conjugate vaccine market, including their market value, share, and competitive positioning.
• Growth Trends Exploration: Assess individual growth patterns and future opportunities in the conjugate vaccine market.
• Segment Contributions: Evaluate how different segments drive overall growth in the conjugate vaccine market.
• Growth Factors: Highlight key drivers and opportunities influencing the expansion of the conjugate vaccine market.
• Industry Challenges: Identify potential risks and obstacles affecting the conjugate vaccine market.
• Competitive Landscape: Review strategic developments in the conjugate vaccine market, including expansions, agreements, and new product launches.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.